Aleksandr Leonidovich Potapov

Aleksandr Leonidovich Potapov

Auto-generated profile, based on publicly available information

Aleksandr Leonidovich Potapov

A.F. Tsyba MRNC, branch of FGBU “NMC of Radiology”, Obninsk, Russia

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Annals of Critical Care
Verified
Journal Article
Open access
ILIlya N. Leiderman
Ilya N. Leiderman
AGA. I. Gritsan
A. I. Gritsan
IZI. B. Zabolotskikh
I. B. Zabolotskikh
VMV. A. Mazurok
V. A. Mazurok
IPI. V. Polyakov
I. V. Polyakov
AYAndrey Yaroshetskiy
Andrey Yaroshetskiy
Numerous publications show that, depending on the type of pathology, protein-energy malnutrition develops in 20– 50 % of surgical patients directly in the hospital in the early postoperative period. Rather a great number of patients with surgical diseases are already hospitalized with varying degrees of malnutrition. From 30 % to 69 % of patients are admitted to the hospital with I–III grade of protein-energy malnutrition and require mandatory nutritional support. Risk factors for protein-energy malnutrition development are determined in 60–70 % of hospitalized patients. This clinical practice recommendations present the basic principles of nutritional support in the perioperative period.

24 May 2022 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
YAYu. V. Averyanova
Yu. V. Averyanova
EBE. M. Batyrshin
E. M. Batyrshin
ADA. E. Demko
A. E. Demko
GIG. E. Ivanova
G. E. Ivanova
VIVladimir Ivashkin
Vladimir Ivashkin
ЮАЮ. В. Аверьянова
Ю. В. Аверьянова
Aim. Current clinical recommendations address the epidemiology, causes, clinical manifestations and pathogenesis of possible immediate and long-term complications, as well as the problematic issues related to treatment and rehabilitation of adult short bowel syndrome patients.Key points. Short bowel syndrome (SBS) is a symptom complex of impaired digestion caused by the reduction of small intestine absorptive surface and manifested by intestinal failure (IF) of various severity (maldigestion and malabsorption) developing into malnutrition and systemic somatogenic disorders. The vital strategic aspects of its treatment are the personalisation of liquid, macro- and micronutrients consumption as well as avoidance of intestinal failure- and parenteral nutrition-associated complications. Various nutritional support regimes and the indications for infusion therapy and maintenance parenteral nutrition are considered in this patient category, also in outpatient settings. To mitigate the dependence on intravenous fluid- and nutrient administration and attain enteral autonomy in SBS-IF patients, the use of recombinant glucagon-like peptide-2 (GLP-2) is justified as exerting a pronounced trophic effect on the epithelial regenerative potential as well as structural and functional adaptation of intestinal mucosa. The SBS-IF patients prescribed with home parenteral nutrition and/or their caregivers should be trained in a special programme that covers the catheter care, preparation of infusion solutions and nutrient mixture container, infusion pump operation as well as the prevention, recognition and management of complications. The main referral indications for small bowel transplantation (SBT) are: fast-progressing cholestatic liver disease-complicated irreversible intestinal failure; thrombosis of two or more central venous conduits used for parenteral nutrition; recurrent catheter-associated bloodstream infection.Conclusion. Current recommendations on diagnosis and treatment as well as the developed criteria of medical aid quality assessment are applicable at different levels of healthcare.

28 June 2023 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ESE. V. Sheberova
E. V. Sheberova
НСН. К. Силантьева
Н. К. Силантьева
TAT. A. Agababian
T. A. Agababian
APA. L. Potapov
A. L. Potapov
ANA. A. Nevolskikh
A. A. Nevolskikh
AKAndrei Kaprin
Andrei Kaprin
The study aimed to summarize the available data on the role of computed tomography in sarcopenia detection in cancer patients. Material and Methods. A literature search was conducted in the Medline, Scopus, Pubmed, and Elibrary systems. More than 100 articles published in 2008-2022 were analyzed. We included 45 articles in this review. Results. According to the European Consensus, sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength due to age-related, neurohumoral changes, malnutrition or muscle catabolism. It is difficult to overestimate the importance of sarcopenia, since this syndrome is one of the five main risk factors for morbidity and mortality in people over 65 years of age. Sarcopenia is mainly observed in inflammatory diseases, malignancy or organ failure. According to most researchers, CT is considered the gold standard method to assess muscle mass and quality. It is a reliable method for quantitative analysis, which was shown in a study based on the comparison of quantitative assessment of various muscle groups based on CT with muscle volume measured on cadaveric tissues. The purpose of this literature review was to highlight the importance of computed tomography for the detection of sarcopenia in clinical practice. Based on the results of the literature analysis, sarcopenia is still a challenge for modern oncology. Sarcopenia negatively affects the prognosis of the disease and quality of life of cancer patients. Sarcopenia may develop due to metabolic changes caused by cancer treatment, as a result of which the degradation of muscle protein begins to prevail over its synthesis. Conclusion. Given the high prevalence and prognostic significance of sarcopenia in oncology, the need for its early diagnosis and active treatment becomes obvious. The use of routine CT examinations for the diagnosis of sarcopenia will allow us to search for possible causes and optimize treatment, determine the likelihood of risks and determine the treatment strategy at an early stage, when therapy can be most effective.

1 January 2021 in Problems of Nutrition
Verified
Journal Article
Closed access
APA.L. Potapov
A.L. Potapov
MSM.а. Servitova
M.а. Servitova
SSS.S. Samarin
S.S. Samarin
VPV.A. Petrov
V.A. Petrov
ILI.N. Leiderman
I.N. Leiderman
Влияние хемосенсорных нарушений на вкусовые предпочтения у онкологических пациентов, получающих дополнительное пероральное питание

3 August 2024 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
AKA. E. Karelov
A. E. Karelov
AOA. M. Ovezov
A. M. Ovezov
IZI. B. Zabolotskikh
I. B. Zabolotskikh
VKV. E. Khoronenko
V. E. Khoronenko
GAG. R. Abuzarova
G. R. Abuzarova
ЮКЮ. Н. Краевская
Ю. Н. Краевская
Introduction. The role of peptides in antinociceptive system regulation has became a subject of interest for scientists worldwide. The first registered peptide analgesic tyrosyl-D-arginyl-phenylalanyl-glycinamide acetate which currently can be used in clinical practice was developed in Russia under the name Taphalgin® (PharmFirma “Sotex”, Russia). The effectiveness and safety of this pharmaceutical in postoperative pain management was evaluated in the all-Russia multicenter prospective observation program NICITA (Non-interventional Clinical Trial of Taphalgin ®).Aim. To analyze the effectiveness and safety of Taphalgin® in postoperative pain management in various surgical fields.Materials and methods. The observational program NICITA included 887 patients including patients with malignant tumors of various locations from 15 study centers in different Russian cities. All patients underwent surgical interventions in various anatomical areas under general, regional and combination anesthesia. The principal scheme of postoperative pain management was based on the multimodal approach which included peptide opioid agonist alongside acetaminophen, cyclooxygenase inhibitors in combination with regional anesthesia or without it. The study also included patients who underwent small-volume surgeries, and pain was managed through Taphalgin® monotherapy with subsequent switch to cyclooxygenase inhibitors. The primary endpoint of the NICITA observational program was response to therapy after the first Taphalgin® administration. Decreased pain syndrome per the numerical rating scale 15–60 min after subcutaneous injection and maintenance of analgesic effect 3 h later were considered treatment response. The secondary endpoints included mean time to analgesia start after administration of the 1st single drug dose (in min), duration of effect, types and frequency of adverse reactions including serious in the central nervous system, pulmonary system, gastrointestinal tract developed during the observational program, as well as patient and research physician satisfaction with pain management. To evaluate the significance of pain intensity change at rest and in motion in time, analysis of variance with repeat measurements was used; for pairwise comparison of two time periods, Student’s t-test for dependent samples was used. The differences were considered significant at p = 0.05.Results. Statistically significant decrease in pain intensity in the total patient group was observed 15 minutes after Taphalgin® administration; it reached its minimum 40 min after the injection (р 0.05). The percentage of patients responding to analgesic therapy with Taphalgin® was 96.5 %. During administration of the drug, insignificant decrease (10–15 mmHg) in arterial blood pressure (1.7 % of cases) and vertigo (1 % of cases) were observed. In some patients, several adverse reactions were observed. Satisfaction with analgesic effect of Taphalgin® was relatively high both in patients and research physicians.Conclusion. Taphalgin® has pronounced analgesic effect and is effective for pain management after surgical interventions of various volumes and injury level. The use of this drug is associated with low rate of adverse reactions and absence of pulmonary depression characterizing opioid agonists. Therefore, Taphalgin® can be recommended for clinical use for postoperative pain management after various types of surgical interventions.

10 March 2021 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
APA. L. Potapov
A. L. Potapov
VKV. E. Khoronenko
V. E. Khoronenko
EGE. V. Gameeva
E. V. Gameeva
ZKZh. V. Khailova
Zh. V. Khailova
ADA. D. Dorozhkin
A. D. Dorozhkin
ВСВ. Ю. Скоропад
В. Ю. Скоропад
The analysis of the current evidence base concerning the use of oral nutritional supplements (ONS) in gastric cancer (GC) has been made. Databases of scientific information eLIBRARY.ru and PubMed were used. Emphasis is placed on randomized clinical trials and meta‑analyses. The application of ONS is suggested for all patients who undergo to surgical treatment for GC. Its use allows increasing protein and energy consumption, improving the quality of life, some parameters of nutritional status and immunity (albumin, blood lymphocytes etc.). In patients with severe malnutrition (SM) ONS can significantly reduce the incidence of clinically important postoperative complications. The use of this type of medical nutrition in the first 5 days after surgery is safe and does not increase the rate of anastomotic leak. After gastrectomy (GE) its administration reduces the time of recovery of bowel motor function and the duration of hospitalization. After distal GE delay of gastric emptying may occur. In patients with SM, early start of enteral nutrition should be considered. After discharge from the hospital ONS can decelerate the progression of malnutrition, improve the tolerance of adjuvant chemotherapy and improve the quality of life. These effects are most clear after GE and in patients with a high risk of malnutrition (NRS‑2002 ≥ 3). There are no evident advantages of any particular type of ONS in patients with GC. When choosing a specific product, preference should be given to formulas with optimal nitrogen: non‑protein kilocalories ratio, osmolarity closest to physiological and individually selected organoleptic properties. It is recommended that the patient consume at least 200–250 ml of the mixture per day, and in the early postoperative period focus have to be made not on the target volume, but on signs of tolerability.